CervoMed Inc. announced positive 24-week interim biomarker data from its Phase 2a trial of neflamapimod in patients with nonfluent variant primary progressive aphasia (nfvPPA), a rare neurodegenerative disease. The data, presented at the CTAD Conference, showed that higher drug exposure resulted in a reduction of neurofilament light chain (NfL), a key biomarker of neuronal damage.

Key Details

  • Primary Finding: Patients with the highest plasma drug levels (upper tertile) showed a median 4.5 pg/mL reduction in NfL over 24 weeks, suggesting a positive drug effect on neurodegeneration.
  • Trial Cohort: The interim data is from the U.S. cohort of 19 patients receiving 40 mg of neflamapimod three times daily. Overall, NfL levels in this group remained stable.
  • Next Steps: Full 24-week biomarker and clinical data, including results from a higher-dose U.K. cohort, are expected to be reported in the first quarter of 2027.